The company expects to have 61.3 million shares in issue following the previously announced share placing, broker option and conversion of convertible loan.
Shares in Diurnal closed up 0.6% at price
Tue, 20th Mar 2018 18:28
The company expects to have 61.3 million shares in issue following the previously announced share placing, broker option and conversion of convertible loan.
Shares in Diurnal closed up 0.6% at price
LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.The intellectual property-based to
Read moreLONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at
Read moreLONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The
Read moreLONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss
Read moreLONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its
Read moreMarch 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal
Read more(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri
Read more(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic
Read more